Michael Sweeney
Director - Business Development & Operations Biodesix
Seminars
Wednesday 17th September 2025
Rapid Turnaround Liquid Biopsy Testing in the Evaluation of RAS Mutational Status During Treatment
10:00 am
- Advances in targeted biomarker testing have progressed in parallel with RAS inhibitor innovation ddPCR is a highly sensitive, targeted, and economical alternative to NGS during longitudinal monitoring of RAS alterations in clinical studies
- Biodesix has demonstrated utility of rapid, high-throughput sample testing from blood samples across multiple cancer types leading to more informed and accelerated decisions by biopharma partners.
